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論 文 内 容 要 旨 
The c-ABL non-receptor tyrosine kinase is a pivotal upstream positive modulator in cellular 
response to DNA damage, which attributes to the activation of p53 family proteins, hence 
the expression of p53 target proteins promoting DNA repair, growth arrest or apoptosis. 
However, a comprehensive understanding of the role of c-ABL kinase in p53-dependent 
transcription of p21CIP1/WAF1 and ensuing cell fate decision is still obscure. Here, I 
demonstrate that c-ABL tyrosine kinase regulates p53-dependent induction of p21. As a 
result, it modulates cell fate decision by p53 in response to DNA damage differently 
according to the extent of DNA damage.  When human cancer cells were treated with DNA 
damaging agent, adriamycin (0.08 µg/ml), p21 was induced following p53 induction. Owing 
largely to p21, a substantial fraction of cells treated with adriamycin were blocked at the G2 
phase of the cell cycle and most cells eventually became senescent. When these cells were 
simultaneously treated with a c-ABL kinase inhibitor, STI571, or a c-ABL-specific siRNA 
along with adriamycin, the p53-dependent p21 induction was dramatically diminished, even 
though p53 is substantially induced. Accordingly, G2-arrest, and cellular senescence largely 
dependent on p21 was substantially abrogated.  On the contrary, when cells were treated 
with a relatively high dose of adriamycin (0.4 µg/ml) cells became apoptotic, and the 
simultaneous presence of a c-ABL kinase inhibitor STI571 augmented the extent of 
apoptosis. I speculate this is due to abrogation of p53-dependent p21 induction, which leads 
to elimination of anti-apoptotic function of p21. In conclusion, c-ABL appears to promote 
senescence or inhibit apoptosis, depending on the extent of DNA damage. These findings 
suggest that the combined use of ABL kinase inhibitor and DNA damaging drug in 
chemotherapy against tumors retaining wild type p53 should be carefully designed. 
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